GLP1R and type 2 diabetes mellitus: Compared to single GLP-1 receptor agonist semaglutide, dual GIP and GLP-1 receptor agonist tirzepatide was associated with a superior reduction in hemoglobin A1c and body weight, and improved kidney outcomes in adults with T2DM with increased cardiovascular risk.